AKAP9
Basic information
Region (hg38): 7:91940840-92110673
Links
Phenotypes
GenCC
Source:
- long QT syndrome 11 (Limited), mode of inheritance: AD
- male infertility with azoospermia or oligozoospermia due to single gene mutation (Moderate), mode of inheritance: AR
- long QT syndrome 11 (Limited), mode of inheritance: AD
- long QT syndrome (Disputed Evidence), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Long QT syndrome 11 | AD | Cardiovascular | In order to prevent sequelae including syncope, cardiac arrest and sudden death prophylactic use of beta blockers in asymptomatic individuals may be beneficial; ICD may be indicated for individuals refractory to beta-blocker treatment or with history of cardiac arrest; Agents that can contribute to prolonged QT or related dysrhythmias should be avoided, as should activities associated with high stress/intense exertion | Cardiovascular | 10220144; 18093912; 20809527; 21430528; 20301308 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the AKAP9 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 14 | 540 | 559 | |||
missense | 1355 | 92 | 1448 | |||
nonsense | 39 | 39 | ||||
start loss | 0 | |||||
frameshift | 57 | 60 | ||||
inframe indel | 21 | 24 | ||||
splice donor/acceptor (+/-2bp) | 15 | 15 | ||||
splice region | 48 | 53 | 7 | 108 | ||
non coding | 17 | 201 | 89 | 307 | ||
Total | 0 | 0 | 1518 | 835 | 99 |
Variants in AKAP9
This is a list of pathogenic ClinVar variants found in the AKAP9 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
7-91940870-G-T | Benign (Mar 03, 2015) | |||
7-91940883-T-TGGC | Long QT syndrome • Congenital long QT syndrome | Conflicting classifications of pathogenicity (May 01, 2023) | ||
7-91940889-C-A | Congenital long QT syndrome | Uncertain significance (Jun 14, 2016) | ||
7-91940940-G-A | Congenital long QT syndrome • Long QT syndrome 11 | Uncertain significance (Sep 20, 2021) | ||
7-91940971-G-A | Benign (Mar 03, 2015) | |||
7-91940976-G-C | Long QT syndrome 11 • Congenital long QT syndrome | Benign/Likely benign (Dec 05, 2021) | ||
7-91940980-G-A | Congenital long QT syndrome | Uncertain significance (Jun 14, 2016) | ||
7-91940993-C-T | Congenital long QT syndrome | Uncertain significance (Jun 14, 2016) | ||
7-91940995-C-T | Congenital long QT syndrome | Uncertain significance (Jun 14, 2016) | ||
7-91941082-G-T | not specified | Benign (May 06, 2024) | ||
7-91941105-G-A | Long QT syndrome | Likely benign (May 08, 2023) | ||
7-91941108-C-T | Cardiovascular phenotype | Likely benign (Jun 13, 2016) | ||
7-91941109-G-C | Cardiovascular phenotype • Long QT syndrome | Conflicting classifications of pathogenicity (May 05, 2023) | ||
7-91941114-G-T | Long QT syndrome | Uncertain significance (Oct 15, 2023) | ||
7-91941116-G-A | Cardiovascular phenotype • Long QT syndrome | Uncertain significance (Jul 03, 2022) | ||
7-91941119-A-C | Cardiovascular phenotype | Uncertain significance (Dec 16, 2021) | ||
7-91941123-G-A | Cardiovascular phenotype • Long QT syndrome | Likely benign (May 18, 2023) | ||
7-91941124-A-C | Cardiovascular phenotype | Uncertain significance (Apr 09, 2023) | ||
7-91941127-C-T | Likely benign (Jan 22, 2018) | |||
7-91941128-T-C | Long QT syndrome | Uncertain significance (Mar 03, 2022) | ||
7-91941129-G-T | Long QT syndrome | Likely benign (Dec 27, 2022) | ||
7-91941131-A-G | Long QT syndrome | Uncertain significance (Jul 16, 2021) | ||
7-91941133-G-A | Long QT syndrome • Cardiovascular phenotype | Uncertain significance (May 29, 2024) | ||
7-91941135-C-T | Cardiovascular phenotype | Likely benign (May 15, 2017) | ||
7-91941136-G-A | Cardiovascular phenotype | Uncertain significance (Jun 24, 2020) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
AKAP9 | protein_coding | protein_coding | ENST00000356239 | 50 | 169807 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
4.52e-17 | 1.00 | 125545 | 0 | 203 | 125748 | 0.000807 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.128 | 1850 | 1.83e+3 | 1.01 | 0.0000895 | 25902 |
Missense in Polyphen | 588 | 654.49 | 0.89841 | 9778 | ||
Synonymous | 0.762 | 625 | 650 | 0.962 | 0.0000317 | 6822 |
Loss of Function | 9.06 | 71 | 214 | 0.332 | 0.0000115 | 2680 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00138 | 0.00137 |
Ashkenazi Jewish | 0.000212 | 0.000198 |
East Asian | 0.000492 | 0.000489 |
Finnish | 0.00122 | 0.00120 |
European (Non-Finnish) | 0.000959 | 0.000950 |
Middle Eastern | 0.000492 | 0.000489 |
South Asian | 0.000732 | 0.000719 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Scaffolding protein that assembles several protein kinases and phosphatases on the centrosome and Golgi apparatus. Required to maintain the integrity of the Golgi apparatus (PubMed:10202149, PubMed:15047863). Required for microtubule nucleation at the cis-side of the Golgi apparatus (PubMed:15047863, PubMed:19242490). Required for association of the centrosomes with the poles of the bipolar mitotic spindle during metaphase (PubMed:25657325). In complex with PDE4DIP isoform 13/MMG8/SMYLE, recruits CAMSAP2 to the Golgi apparatus and tethers non-centrosomal minus-end microtubules to the Golgi, an important step for polarized cell movement (PubMed:27666745, PubMed:28814570). In complex with PDE4DIP isoform 13/MMG8/SMYLE, EB1/MAPRE1 and CDK5RAP2, contributes to microtubules nucleation and extension also from the centrosome to the cell periphery (PubMed:29162697). {ECO:0000269|PubMed:10202149, ECO:0000269|PubMed:15047863, ECO:0000269|PubMed:19242490, ECO:0000269|PubMed:25657325, ECO:0000269|PubMed:27666745, ECO:0000269|PubMed:28814570, ECO:0000269|PubMed:29162697}.;
- Disease
- DISEASE: Long QT syndrome 11 (LQT11) [MIM:611820]: A heart disorder characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress, and can present with a sentinel event of sudden cardiac death in infancy. {ECO:0000269|PubMed:18093912}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- G Protein Signaling Pathways;NO-cGMP-PKG mediated Neuroprotection;Disease;Signal Transduction;protein kinase a at the centrosome;Neuronal System;Phase 2 - plateau phase;Phase 3 - rapid repolarisation;Cardiac conduction;Muscle contraction;Regulation of PLK1 Activity at G2/M Transition;Recruitment of mitotic centrosome proteins and complexes;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;Centrosome maturation;AURKA Activation by TPX2;RAF/MAP kinase cascade;MAPK1/MAPK3 signaling;MAPK family signaling cascades;G2/M Transition;Mitotic G2-G2/M phases;Recruitment of NuMA to mitotic centrosomes;Mitotic Prometaphase;Neurotransmitter receptors and postsynaptic signal transmission;Transmission across Chemical Synapses;M Phase;Ras activation upon Ca2+ influx through NMDA receptor;CREB phosphorylation through the activation of Ras;Unblocking of NMDA receptor, glutamate binding and activation;CREB phosphorylation through the activation of CaMKII;Post NMDA receptor activation events;Activation of NMDA receptor and postsynaptic events;Cell Cycle;Cell Cycle, Mitotic;Anchoring of the basal body to the plasma membrane;Signaling by BRAF and RAF fusions;Oncogenic MAPK signaling;Diseases of signal transduction;Cilium Assembly;Organelle biogenesis and maintenance
(Consensus)
Recessive Scores
- pRec
- 0.111
Intolerance Scores
- loftool
- 0.933
- rvis_EVS
- 0.22
- rvis_percentile_EVS
- 68.45
Haploinsufficiency Scores
- pHI
- 0.146
- hipred
- Y
- hipred_score
- 0.551
- ghis
- 0.550
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.444
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | High | High | High |
Primary Immunodeficiency | High | High | High |
Cancer | High | High | High |
Mouse Genome Informatics
- Gene name
- Akap9
- Phenotype
- hematopoietic system phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); immune system phenotype; skeleton phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); craniofacial phenotype; homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- G2/M transition of mitotic cell cycle;microtubule nucleation;signal transduction;negative regulation of adenylate cyclase activity;chemical synaptic transmission;regulation of G2/M transition of mitotic cell cycle;positive regulation of microtubule polymerization;positive regulation of peptidyl-serine phosphorylation;response to electrical stimulus;maintenance of centrosome location;regulation of membrane repolarization;regulation of ventricular cardiac muscle cell membrane repolarization;cellular response to cAMP;regulation of heart rate by cardiac conduction;ciliary basal body-plasma membrane docking;regulation of cardiac muscle cell action potential involved in regulation of contraction;regulation of postsynaptic neurotransmitter receptor activity;positive regulation of potassium ion transmembrane transporter activity;regulation of Golgi organization
- Cellular component
- Golgi apparatus;Golgi stack;cis-Golgi network;centrosome;cytosol;cytoskeleton;voltage-gated potassium channel complex;neuronal cell body;intracellular membrane-bounded organelle;dendritic branch;synaptic membrane;glutamatergic synapse;extrinsic component of postsynaptic density membrane
- Molecular function
- DNA binding;signaling receptor binding;protein binding;potassium channel regulator activity;protein-containing complex scaffold activity;protein kinase A regulatory subunit binding;ion channel binding